Clinical Trials Logo

Filter by:
NCT ID: NCT05888844 Recruiting - Clinical trials for Cutaneous Squamous Cell Carcinoma

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.

NCT ID: NCT05888831 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Start date: June 6, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

NCT ID: NCT05888662 Recruiting - Clinical trials for Ischemic Cardiomyopathy

Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)

EPIC-VT
Start date: October 23, 2023
Phase: N/A
Study type: Interventional

Radiofrequency ablation of ventricular tachycardias (VTs) is the gold standard treatment of refractory VTs in patients with ischaemic heart disease. In this setting, ablation is usually performed endocardially. However, even after a procedural success there is a high risk of recurrence, particularly due to the inability to create transmural lesions. Indeed, only the endocardium of the LV has been ablated, while a significant part of the arrhythmia substrate may be located on the other side of the myocardial thickness, on the epicardial side of the LV. First described in 1996, epicardial ablation, performed via a percutaneous subxyphoid approach, has since undergone considerable development. Electrophysiologists often use a double endo- and epicardial approach as first line therapy for the ablation of VTs complicating myocarditis or arrhythmogenic dysplasia of the right ventricle, where the substrate is most often epicardial. For VT in ischaemic heart disease, electrophysiologists perform endocardial ablation, and often perform epicardial ablation only after several endocardial failures. Several observational studies suggest that a combined endo- and epicardial approach as first line therapy is associated with a reduced risk of VT recurrence. Since recurrent VT in patients with ischaemic heart disease as a prognostic impact in terms of morbidity and mortality, it appears essential to optimise rhythm management by ablation, by offering a combined approach from the as first approach to reduce the risk of recurrences. The aim of our prospective, multicentre, controlled, randomized study is therefore to compare the rate of VT recurrence after ablation performed as first line therapy either by endocardial approach alone or by combined endo-epicardial approach.

NCT ID: NCT05888415 Not yet recruiting - Well-being Clinical Trials

WELL-being Improvement Following Sophrology Practice

SoWell-Learn
Start date: September 2023
Phase:
Study type: Observational

Stress and psychosocial risks are a major public health problem.Sophrology is a psycho-corporal method exclusively verbal and non-tactile used as a therapeutic technique. It combines a set of techniques that will act both on the body and on the mind through breathing exercises, muscle relaxation and mental imagery (or visualization). It allows to find a state of well-being and to activate all physical and psychological potential in order to acquire a better knowledge of oneself. Sophrology demonstrated some benefits on symptoms of patients. However, these approaches have never been evaluated with a prolonged follow-up of several months, with biological measures or with adjustments according to the levels of mastery of sophrology. This project proposes to evaluate the effects of sophrology practice. The investigators aim to evaluate both subjective and objective measures of stress.

NCT ID: NCT05888324 Recruiting - Clinical trials for Post-Dural Puncture Headache

Factors Associated With the Onset of Chronic Headaches in Patients Who Received a Blood Patch in Post Partum

CHROBLOOD
Start date: June 6, 2023
Phase:
Study type: Observational

The purpose of this study is to identify possible links between conditions for carrying out a blood patch (BP) to treat accidental post dural puncture acute headache (PDPH) in the early post partum period and occurrence of chronic headaches at 1 and 6 months.

NCT ID: NCT05888194 Recruiting - Clinical trials for Perineal Tear and Episiotomy

The Effect of Mucogyne® Gel on Wound Healing

ARTHEMIS
Start date: June 12, 2023
Phase: N/A
Study type: Interventional

The aim of this post-market clinical follow up study is to confirm the efficacy and safety of topical application of Mucogyne® gel in the process of wound healing, when used in accordance with its approved labeling, in the context of postpartum perineal wounds.

NCT ID: NCT05887440 Recruiting - Clinical trials for Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis)

Isokinetic Strength Training in Hemiparetic Patient With Knee Extension Thrust

ISOWALK
Start date: August 21, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the impact of an isokinetic strength training of knee flexor and extensor muscles on walking performance in hemiparetic patients with knee extension thrust.

NCT ID: NCT05887323 Active, not recruiting - Heart Failure Clinical Trials

LBBAP Data Collection Registry

Start date: April 25, 2023
Phase:
Study type: Observational

The purpose of this registry is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients already implanted with the Tendril STS 2088 lead.

NCT ID: NCT05887206 Completed - Myeloma Multiple Clinical Trials

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Start date: May 2, 2022
Phase:
Study type: Observational

Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM). It is used in multiple myeloma refractory to an immunomodulatory drug or proteasome inhibitor and refractory and/or intolerant to an anti-CD38 monoclonal antibody. It has been found that the immunotherapy causes corneal side effects, Microcyst-like Epithelial Changes (MECs). They are round-shaped corneal inclusions that migrate from the peripheral cornea to the center, causing blurry vision, dryness and refractive shifts depending on their location and density.

NCT ID: NCT05887089 Recruiting - Biological Samples Clinical Trials

Analytical Impact of the Transport of Pathological Biological Material by Drone

PATH-AIRCHU
Start date: May 22, 2023
Phase:
Study type: Observational

The Hospital Group of Territory Somme Littoral Sud, through its biology sector and in partnership with the company DELIVRONE, aims to engage in the experiment of transporting biological samples by means of a drone platform. Transport by air will be between the CHAM, the Abbeville Hospital and the CHU Amiens-Picardie by flying as much as possible over the waterways via the Somme. With a flight speed of around 100km/h at an altitude between 80 and 120 m, drones will be able to connect sites in less than an hour by transporting packages between 2 and 3 kg. Powered by propellers connected to rechargeable batteries, these drones do not emit CO2. This type of transport has not been validated in France by measuring the analytical impact of transport constraints for medical biology, and has never been evaluated according to the criteria of ISO 15189 standard allowing the certification of medical biology laboratories. Validation steps of this transportation method are therefore necessary on pathological samples prior to routine use. The aim of the project is to verify the absence of analytical impact of the transport of pathological biological samples by drone under defined flight conditions, according to the ISO15189 norm.